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Recurrent stroke in childhood cancer
survivors
ABSTRACT
Objective: To estimate the rates and predictors of recurrent stroke among survivors of pediatric
cancer who have had a first stroke.
Methods: The Childhood Cancer Survivor Study is a retrospective cohort study with longitudinal
follow-up that enrolled 14,358 survivors (,21 years old at diagnosis; diagnosed 1970–1986;
survived $5 years after cancer diagnosis) and followed them prospectively since 1994. We sur-
veyed 443 survivors who reported a first stroke to identify recurrent stroke, and estimated
recurrent stroke rates $5 years after cancer diagnosis.
Results: Among 329 respondents (74% response rate), 271 confirmed a first stroke at a median
age of 19 years (range 0–53), and 70 reported a second stroke at a median age of 32 years (range
1–56). In a multivariable Cox proportional hazards model, independent predictors of recurrent
stroke included cranial radiation therapy (CRT) dose of $50 Gy (vs none, hazard ratio [HR] 4.4;
95% confidence interval [CI] 1.4–13.7), hypertension (HR 1.9; 95%CI 1.0–3.5), and older age at
first stroke (HR 6.4; 95% CI 1.8–23; for age $40 vs age 0–17 years). The 10-year cumulative
incidence of late recurrent stroke was 21% (95% CI 16%–27%) overall, and 33% (95% CI
21%–44%) for those treated with $50 Gy of CRT.
Conclusion: Survivors of childhood cancer, particularly those previously treatedwith high-dose cra-
nial radiation, have a high risk of recurrent stroke for decades after a first stroke. Although these
strokes are mostly occurring in young adulthood, hypertension, an established atherosclerotic risk
factor, independently predicts recurrent stroke in this population. Neurology® 2015;85:1056–1064
GLOSSARY
CCSS 5 Childhood Cancer Survivor Study; CI 5 confidence interval; IQR 5 interquartile range; IRB 5 institutional review
board; NDI 5 National Death Index; NF1 5 neurofibromatosis type 1.
Prior studies have shown that childhood cancer survivors are at increased risk of stroke but many
questions remain. Recent studies suggest that stroke risk remains elevated decades after cancer
treatment.1–3 Cranial radiation therapy is a particularly strong predictor of first stroke, with an
apparent dose-dependent effect.1,2,4,5 The etiology of stroke in these cases is likely a radiation-
induced arteriopathy, which can lead to large or small vessel infarction, although the mecha-
nisms underlying this arteriopathy have yet to be established.6,7 In a population-based cohort of
children with ischemic stroke of any etiology, those with an underlying arteriopathy had an
extraordinarily high risk of recurrent stroke: 66% within 5 years of the initial stroke.8 Children
with radiation-induced arteriopathy most likely fall in this high-risk group, but there are few
data regarding rates and predictors of recurrent stroke in pediatric cancer survivors. A better
understanding of risk factors for recurrent stroke is needed to develop strategies for secondary
stroke prevention in this high-risk population.
The Childhood Cancer Survivor Study (CCSS) is a retrospective cohort study with prospec-
tive follow-up.9,10 We used a previously identified subcohort with self-reported first stroke2 and
administered a new stroke survey to test the hypotheses that (1) stroke recurrence rates are high
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in childhood cancer survivors with first stroke
and (2) cranial radiation therapy is a predictor
of recurrent stroke.
METHODS Cohort. CCSS is an NIH-funded cohort study
that originally identified 20,690 survivors of childhood cancer
at 26 institutions in the United States and Canada, and
recruited 14,358 of them into long-term follow-up (figure e-1
on the Neurology® Web site at Neurology.org). Eligibility
criteria for enrollment are fully described elsewhere, and
included age ,21 years at cancer diagnosis, diagnosis between
1970 and 1986, survival for $5 years after diagnosis, and initial
cancer treatment received at a CCSS collaborating institution.11
Extensive details regarding baseline characteristics of patients (e.g.,
sex and race), the cancer type, radiation doses, and therapies
received were collected at the time of enrollment. Late effects of
cancer and cancer therapy have been assessed prospectively through
4 follow-up surveys available for review at http://ccss.stjude.org.
Vital status for participants was assessed based on linkage to the
National Death Index (NDI). A detailed description of the CCSS
cohort, including comparisons of survey respondents vs
nonrespondents, has been published previously.9–11
Standard protocol approvals, registrations, and patient
consents. The initial CCSS study was approved by institutional
review boards (IRBs) at each collaborating institution and follow-
up surveys, including the stroke survey, were approved by the IRB
at St. Jude Children’s Research Hospital, home of the
Coordinating Center.
Stroke subcohort. CCSS patients were eligible for inclusion in
the current study of recurrent stroke if they (or their proxy, if
deceased) had responded either “yes” or “not sure” to questions
about first stroke on any of the prior outcomes questionnaires.
This cohort of patients with reported first stroke has been
described recently.2 All eligible patients were contacted by mail
with a new survey focused on first and recurrent stroke. If a
potential patient was deceased, a modified survey was sent to
his or her proxy. Those who did not respond within 30 days to
the mailing were subsequently contacted by telephone. In addi-
tion, the survey was remailed to nonrespondents 5 and 9 months
after the first mailing, followed by telephone calls 30 days after
each mailing.
2011 stroke survey. Patients/proxies were given the option of
completing the survey by mail, online, or by telephone. The
stroke survey (available at the CCSS Web site, http://ccss.
stjude.org) first defined stroke using lay terminology, then
asked the patient (or proxy) to confirm his or her prior report
of a stroke. If confirmed, the survey asked detailed questions
about the original stroke (presentation, evaluation, and treatment),
and then asked if and when the patient had a recurrent stroke.
Data analysis. We used time-to-event methodology to estimate
cumulative incidence rates and predictors of stroke recurrence.
Because patients were enrolled in CCSS only if they had
survived 5 years after cancer diagnosis, patients are considered
to have entered the study at 5 years postdiagnosis when the
time period of observation for late effects began, and this
defines the cohort of subjects at risk of these conditions. The
questionnaires asked about stroke retrospectively, thus the
survivor/proxy could have reported a first or recurrent stroke at
an age prior to 5 years after diagnosis. However, to avoid
survival bias, such first and recurrent strokes are summarized in
descriptive tables, but not included in the time-to-event
analysis. The time-to-event analyses utilized left truncation, with
the period at risk for an observable recurrent stroke beginning at
the time of the first stroke, or at 5 years postdiagnosis (the time
point of study eligibility), whichever was later. Patients whose
response to the recurrent stroke question was missing or “I don’t
know”were excluded from the analysis. Patients with missing age at
recurrent stroke or age at recurrent stroke prior to study entry were
also excluded (figure e-1).
Time from first stroke to initial recurrent stroke was based on
reported integer ages, with age converted to a date equivalent to
the midpoint of the year of the reported age. If the reported age at
recurrent stroke was equivalent to the age at first stroke, 2 months
(60 days) of follow-up was assigned, based on the median time
found in other studies.8
In the absence of recurrent stroke, patients were censored at
the date of the last questionnaire completed by the patient or
his or her proxy, and death was treated as a competing risk event
for the calculation of cumulative incidence.12 Based on cause of
death from the NDI, among all CCSS patients, there were 23
deaths considered to be stroke-related. However, 17 of these
patients died after the last completed questionnaire, with no indi-
cation of a stroke on a prior outcome questionnaire, so they were
not included in the 2011 stroke survey. Of the remaining 6
patients, 3 had proxy responses and were included in the time
to event analysis, with 2 as recurrent stroke events and one cen-
sored at death (likely death from first stroke). We calculated
unadjusted hazard ratios (HRs) as a measure of relative risk using
Cox proportional hazards techniques, where time to event was
censored at last contact or death. To determine independent
predictors of recurrent stroke, we evaluated multivariable Cox
proportional hazards models,13 using univariate screening with
a p value cutoff of 0.10 for inclusion in the model. Sex, race/
ethnicity (white non-Hispanic vs other), and age at diagnosis were
included in all models as a priori covariates. The primary predic-
tor of interest was total dose of cranial radiation therapy, as
defined and categorized for the CCSS study of predictors of first
stroke.2 Other predictors included age at first stroke, cancer type,
chemotherapy, diagnosis of neurofibromatosis type 1 (NF1),
hypertension, smoking, and diabetes. NF1 was based on self-
report on any questionnaire. Hypertension, smoking, and diabe-
tes were treated as time-dependent variables that switched from
not present to present at the earliest self-reported age at diagnosis
or usage, and were defined as in our prior report.2
RESULTS Within the overall CCSS cohort of
14,358 childhood cancer survivors followed for a
mean of 23 years postdiagnosis, a total of 292 had re-
ported a first stroke after study entry by the time of
the third follow-up CCSS survey. An additional
172 patients reported a stroke prior to study entry
(i.e., within the first 5 years after cancer diagnosis),
and 25 indicated “not sure” on the third survey. Of
these 489 patients with possible first stroke,
questionnaires were mailed to 334 live patients and
109 proxies of deceased patients; 329 responses were
received (74% response rate; figure e-1). Key
characteristics of subjects such as sex, race, age at
cancer diagnosis, age at first stroke, age at last
follow-up, and radiation dose did not differ
significantly between those who responded to the
survey compared to those who did not (x2 test; see
table e-1).
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First stroke in childhood cancer survivors. Among the re-
spondents, 271 confirmed a first stroke. The median
time from cancer diagnosis to first stroke was 10 years
(interquartile range [IQR] 21 years). The most com-
mon underlying cancer types were brain tumors
(44%) and leukemia (28%); the majority had received
cranial radiation, although 22% of the stroke cohort
had received neither cranial nor neck radiation (table
e-2). The median age at first stroke was 19 years (table
e-2). The most common presenting features were uni-
lateral weakness (64%) and difficulty walking (63%)
and speaking (60%); a minority of respondents
(37%) reported complete recovery from the first stroke.
Among 79 patients with a self-reported ischemic stroke,
51 (65%) reported poststroke treatment with an
antithrombotic agent (antiplatelet or anticoagulant, in
hospital or at home), as well as 13 (20%) of 65
patients with a self-reported hemorrhagic stroke.
Recurrent stroke in childhood cancer survivors. Of the
271 patients with first stroke, 70 reported a second
stroke, 164 reported no recurrence, and 37 were
unsure whether there was a recurrence or skipped
the question. The median age at second stroke was
32 years (table 1); the median time from cancer diag-
nosis to second stroke was 23 years (IQR 19 years).
The most common presenting features were difficulty
speaking (64%) and walking (61%) and unilateral
weakness (47%); only 27% reported a complete
recovery from the second stroke. Among the 271
patients with first stroke, 58 could not be included
in the time-to-event analysis (figure e-1); of the
remaining 213, 52 reported a second stroke. The
10-year cumulative incidence of second stroke was
21% (95% confidence interval [CI] 16–27) overall
(figure 1A), 33% (95% CI 21–44) for those treated
with $50 Gy of cranial radiation, and 11% (95% CI
0%–21%) for those who received no radiation (table 2).
Predictors of recurrent stroke in childhood cancer
survivors. Stratified cumulative incidence curves sug-
gested that cranial radiation dose, cancer type, and
age at first stroke modified recurrent stroke risk
(figure 1, B–D); total cranial radiation dose of $50
Gy, brain tumors, and age .17 years at first stroke
were significant predictors of recurrence on univariate
analysis (table 3). Hypertension (reported at any point
prior to the second stroke or loss to follow-up) was also
predictive in a univariate analysis. These remained
independent predictors of recurrence on multivariate
analysis (table 4); cancer type was not included in the
final model due to collinearity with cranial radiation
dose, and history of NF1 could not be included since
only 3 patients reported a positive history.
DISCUSSION Survivors of childhood cancer with
self-reported first stroke are at high risk for
Table 1 Characteristics of second stroke in 70
childhood cancer survivors reporting a
recurrent stroke in the 2011 stroke
survey
Characteristics
Median (range)
or n (%)
Age at second stroke, y 32 (1–56)
Age at second stroke, y (categorical)
<18 15 (21)
18–29 14 (20)
30–39 19 (27)
401 15 (21)
Missing 7 (10)
Type of second stroke
Ischemic 21 (30)
Hemorrhagic 15 (21)
Not sure 25 (36)
Missing 9 (13)
Second stroke symptoms lasted >24 h
Yes 49 (70)
No 15 (21)
Do not know 6 (9)
Characteristics of second stroke
Difficulty speaking 45 (64)
Difficulty walking 43 (61)
Unilateral weakness 33 (47)
Visual changes 30 (43)
Headache at the time of stroke 25 (36)
Seizure at the time of stroke 23 (33)
Unilateral numbness 23 (33)
Dizziness 19 (27)
Bilateral weakness 14 (20)
Bilateral numbness 8 (11)
No symptoms (silent stroke) 5 (7)
Brain imaging performed
Both CT and MRI 21 (30)
CT 15 (21)
MRI 13 (19)
No brain imaging done 11 (16)
Imaging not known 10 (14)
Recovery from second stroke
Complete 19 (27)
Partial 28 (40)
No recovery 17 (24)
Do not know 6 (9)
More than one recurrent stroke?
Yes 22 (31)
No 48 (69)
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recurrent stroke in the decade following the first
stroke. Predictors of recurrent stroke are similar to
predictors of first stroke, including high-dose cranial
radiation therapy and hypertension. Older age at
first stroke also predicted risk of recurrence.
The cumulative rate of recurrent stroke in the gen-
eral population of young adults (,50 years of age) has
been estimated at approximately 10% by 10 years
after a first ischemic stroke.14,15 In our cohort of child-
hood cancer survivors, the first strokes tended to
occur in young adulthood, but the recurrent stroke
rate was, overall, double that for young adults in gen-
eral, with a 10-year cumulative rate of 21%. Prior
cranial radiation therapy ($50 Gy) was a significant
predictor of recurrent stroke risk. Those who received
no cranial radiation had a recurrent stroke risk of 11%
at 10 years, similar to young adults in general; the risk
tripled for those who received $50 Gy (33% at 10
years). Prior neck radiation was not a significant pre-
dictor of recurrent stroke risk in our study. However,
our study was likely underpowered to detect an asso-
ciation between neck radiation and recurrent stroke.
There is one published estimate of recurrent stroke
risk in this setting: a single-institution retrospective
study, performed by authors of this report (H.J.F.,
S.M.), examined stroke risk among 19 childhood can-
cer survivors who had been treated with high-dose
cranial or cervical radiation and reported a first stroke
at any time (including those in the first 5 years after
cancer diagnosis).3 Of the 19 patients with a first
stroke (median age at first stroke of 24 years), 6 had
recurrent strokes at a median interval of 15 months
(IQR 6 months–3.2 years), yielding a cumulative 10-
year recurrence estimate of 59% (95% CI 27–92).
Figure 1 Cumulative incidence of recurrent stroke in childhood cancer survivors
Cumulative incidence of recurrent stroke after study entry among 213 childhood cancer survivors with self-reported first stroke and responses regarding recur-
rent stroke on the 2011 stroke questionnaire: unstratified with 95% confidence interval (A), and stratified by maximum dose of cranial radiation therapy to any
brain segment (B), cancer type (C), and age in years at first stroke (D). Curves begin at the timeof first stroke or, if first stroke occurred prior to study entry, at study
entry. Curves are displayed out to time point where fewer than 10 survivors were at risk. CNS 5 central nervous system tumors; HD 5 Hodgkin disease.
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This higher point estimate, when compared with
33% (95% CI 21–44) for the CCSS stroke cohort
treated with $50 Gy cranial radiation, may suggest
underreporting of stroke in the current study. How-
ever, other methodologic differences, including dif-
ferences in sample size, may also explain the apparent
difference.
The mechanism underlying how cranial radiation
increases stroke risk remains to be elucidated. Studies
have shown that radiation therapy is associated with
an occlusive disease of arteries located within or
nearby the radiation field.7,16 Among children with
arterial ischemic stroke of any cause, the presence of
a cerebral arteriopathy, and of moyamoya in particu-
lar, has been shown to be the strongest predictor of
recurrent stroke.8,17 While the development of moya-
moya is a relatively early phenomenon, the elevated
risk of first stroke in childhood cancer survivors ap-
pears to persist, and even increase, decades after treat-
ment, suggesting a second mechanism for a delayed
radiation arteriopathy.1,2
A prior CCSS study found that hypertension and
black race—both established risk factors for athero-
sclerosis18,19—independently increased risk of first
stroke in childhood cancer survivors.2 These findings,
in addition to extensive clinical and laboratory evi-
dence suggesting that neck radiation causes acceler-
ated atherosclerosis of cervical vessels,7,20,21 led to a
hypothesis that cranial radiation may increase stroke
risk by accelerating the development of intracranial
atherosclerosis. In our study, we similarly found that
hypertension independently predicted risk of recur-
rent stroke; there was a nonsignificant trend toward
an association with diabetes. Age $17 years at the
time of first stroke also predicted recurrence, with risk
increasing with each decade of advancing age. A
recent analysis from the CCSS also showed that child-
hood cancer survivors have premature aging and early
onset of cardiovascular disease.22 This lends further
support to the hypothesis that early-onset atheroscle-
rosis is on the causal pathway from cranial radiation
to ischemic stroke, and suggests that earlier screening
for modifiable atherosclerotic risk factors could be an
avenue for improving both cardiovascular and cere-
brovascular outcomes.
Strengths of this study include the relatively large
size of the cohort, the long duration of follow-up, and
the quality of the data on predictors such as cancer
treatments. However, our findings must be consid-
ered in the context of certain limitations. It was not
Table 2 Incidence of recurrent stroke after study entrya among 213 childhood cancer survivors with
self-reported first stroke, and responses regarding recurrent stroke on the 2011 survey, stratified
by cancer type and radiation therapy
Group
First
stroke, n
Recurrent
stroke, n
10-y cumulative
incidence
HR (95% CI) p ValueRate, % 95% CI
All cancer survivors 213 52 21 16–27
With RT 157 45 24 17–31 3.2 (1.1–8.9) 0.03
Without RT 37 4 11 1–21 Ref
Unknown RT 19 3
Brain tumor 83 29
With RT 70 26 31 20–43 4.3 (0.6–32.0) 0.15
Without RT 8 1 NE Ref
Unknown RT 5 2
Leukemia 68 8
With RT 49 8 17 6–28 NE
Without RT 11 0 NE
Unknown RT 8 0
Hodgkin disease 21 5
With RT 18 4 20 0–39 0.6 (0.1–6.3) 0.69
Without RT 2 1 NE Ref
Unknown RT 1 0
Abbreviations: CI 5 confidence interval; HR 5 hazard ratio for recurrent stroke in those with vs without exposure to
radiation therapy; NE 5 nonestimable due to low number of outcomes; Ref 5 reference; RT 5 prior direct cranial radiation
therapy or scatter.
aSubjects entered the study observation period at 5 years post cancer diagnosis.
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Table 3 Univariate predictors of recurrent stroke after study entry among 213 childhood cancer survivors
with self-reported first stroke and responses regarding recurrent stroke
Characteristics
Recurrence
(n 5 52), n (%)
No recurrence
(n 5 161), n (%) HR (95% CI) p Value
Male sex 29 (56) 82 (51) 1.3 (0.8–2.3) 0.32
Race
White, non-Hispanic 39 (75) 129 (80) Ref
Black 4 (8) 8 (5) 1.6 (0.6–4.4) 0.39
Other 9 (17) 24 (15) 1.3 (0.6–2.7) 0.49
Age at cancer diagnosis, y, median (range) 8 (0–20) 7 (0–20)
Age at cancer diagnosis, y
0–4 14 (27) 58 (36) 0.7 (0.3–1.6) 0.43
5–9 18 (35) 35 (22) 1.4 (0.6–3.0) 0.39
10–14 10 (19) 38 (24) 0.9 (0.4–2.1) 0.75
15–20 10 (19) 30 (19) Ref
Cancer diagnosis
Brain tumor 29 (56) 54 (34) 3.5 (1.6–7.7) 0.0017
Leukemia 8 (15) 60 (37) Ref
Hodgkin disease 5 (10) 16 (10) 2.7 (0.9–8.2) 0.090
Othera 10 (19) 31 (19) 2.3 (0.9–5.8) 0.082
Cranial radiation therapy, maximum dose, Gy
None 4 (8) 33 (20) Ref
0.01–29.9 6 (12) 38 (24) 1.3 (0.4–4.5) 0.70
30–49.9 4 (8) 10 (6) 3.3 (0.8–13.4) 0.088
‡50 26 (50) 41 (25) 4.8 (1.7–13.7) 0.0038
Indirect 9 (17) 23 (14) 3.4 (1.0–11.2) 0.043
Unknown 3 (6) 16 (10) —
Any neck radiation
Yes 12 (23) 42 (26) 1.0 (0.5–1.9) 0.92
No 37 (71) 103 (64) Ref
Unknown 3 (6) 16 (10) —
Radiation to neck or brain
Direct neck, no direct brain radiation 5 (10) 14 (9) 2.0 (0.6–6.0) 0.24
Direct brain radiation 36 (69) 90 (56) 2.0 (0.9–4.2) 0.080
No neck or brain direct radiation 8 (15) 41 (25) Ref
Unknown 3 (6) 16 (10) —
Age at first stroke, y, median (range) 30 (2–49) 17 (0–49)
Age at first stroke, y
0–17 12 (23) 85 (53) Ref
18–29 13 (25) 27 (17) 4.5 (2.0–10.4) 0.0003
30–39 19 (37) 32 (20) 6.4 (2.9–14.4) ,0.0001
‡40 8 (15) 17 (11) 5.9 (2.2–15.6) 0.0004
Time from cancer diagnosis to first stroke, y
Stroke before cancer diagnosis 0 (0) 5 (3)
<2 5 (10) 46 (29) Ref
2–5 4 (8) 23 (14) 1.7 (0.5–6.3) 0.44
6–10 4 (8) 15 (9) 4.1 (1.1–15.5) 0.040
‡11 39 (75) 72 (45) 9.2 (3.4–25.0) ,0.0001
Continued
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feasible to obtain medical records or brain imaging to
confirm the reported strokes in our cohort. Hence,
all strokes (first and recurrent) were measured by self-
report or proxy report, which likely led to some
misclassification, and also precluded reliable subclassi-
fication of stroke type (ischemic vs hemorrhagic).
Subclinical or silent strokes may have gone undetected,
resulting in an underestimation of total stroke fre-
quency in the cohort. However, the 2011 stroke survey
improved upon prior CCSS survey measurements of
stroke outcomes by providing lay definitions of stroke
before asking respondents to confirm their report of
stroke, and by including questions regarding stroke
presentation and treatment. Indeed, 55 previously re-
ported first strokes were not confirmed on the stroke
survey, suggesting that the lay definitions may have
improved the respondents’ understanding of the ques-
tion. Furthermore, our high response rate to the stroke
survey suggests that there was no significant participa-
tion bias (i.e., both patients with and without recurrent
stroke responded to the stroke survey). Our measure-
ments of atherosclerotic risk factors were also based on
self-report, and we had to make assumptions regarding
the onset of these risk factors. Also, because patients
were enrolled in CCSS only if they survived 5 years
post cancer diagnosis, our study is missing children
who died within the first 5 years (a group that may
have been at particularly high risk for first and recur-
rent stroke). Hence, our results are only generalizable
to $5-year survivors of childhood cancer, and not to
children with more recent diagnoses. Cerebral or cer-
vical arteriopathies are the strongest predictor of recur-
rent stroke in children8; however, we had no access to
imaging, including vascular imaging, so could not
assess whether a cerebral arteriopathy was on the causal
pathway between radiation and recurrent stroke.
Finally, although we collected data on antithrombotic
use, because we could not reliably distinguish ischemic
from hemorrhagic stroke, and because of concerns for
confounding by indication, we could not perform a
meaningful analysis of efficacy of such therapy in
reducing risk of recurrent ischemic stroke.
Table 3 Continued
Characteristics
Recurrence
(n 5 52), n (%)
No recurrence
(n 5 161), n (%) HR (95% CI) p Value
First stroke symptom duration >24 h 40 (77) 96 (60) 1.9 (1.0–3.6) 0.057
Presentation with hemiparesis 30 (58) 111 (69) 0.6 (0.3–1.0) 0.064
Stroke risk factorsb
Narrowing of blood vessels to brain 4 (8) 9 (6) 1.3 (0.5–3.6) 0.62
Moyamoya 5 (10) 5 (3) 2.6 (1.0–6.5) 0.044
Hypertension 24 (46) 48 (30) 3.3 (1.9–5.7) ,0.0001
Diabetes mellitus 5 (10) 12 (7) 2.3 (0.9–5.7) 0.08
Smoking (ever) 7 (13) 43 (27) 0.7 (0.3–1.6) 0.45
Abbreviations: CI 5 confidence interval; HR 5 hazard ratio from univariate Cox proportional hazards models; Ref 5
reference.
Frequencies shown here represent onset at any time prior to recurrence/last follow-up.
aWilms tumor, non-Hodgkin lymphoma, soft tissue sarcoma, bone cancer, neuroblastoma.
bHypertension, diabetes, and smoking were treated as time-dependent in the models (i.e., the value of the covariate for an
individual could change with age).
Table 4 Independent predictors of recurrent stroke after study entry among
213 childhood cancer survivors with self-reported first stroke and
responses regarding recurrent stroke
Predictor HR (95% CI) p Value
Male sex 0.9 (0.5–1.7) 0.81
Black or other race vs white non-Hispanic 1.7 (0.8–3.5) 0.17
Age at cancer diagnosis, y
0–4 1.2 (0.4–3.1) 0.78
5–9 1.7 (0.7–4.0) 0.26
10–14 0.6 (0.2–1.7) 0.35
15–20 Ref
Cranial radiation therapy, maximum dose
None Ref
0.01–29.9 Gy 1.7 (0.5–6.3) 0.41
30–49.9 Gy 3.1 (0.7–13.4) 0.12
‡50 Gy 4.4 (1.4–13.7) 0.011
Indirect radiation 2.0 (0.6–6.6) 0.27
Age at first stroke, y
0–17 Ref
18–29 3.4 (1.3–8.8) 0.014
30–39 5.4 (2.0–15.0) 0.0012
‡40 6.4 (1.8–22.6) 0.0039
Hypertension 1.9 (1.0–3.5) 0.052
Abbreviations: CI 5 confidence interval; HR 5 hazard ratio from multivariate Cox propor-
tional hazards models (all variables included in the model are shown); Ref 5 reference.
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Dramatic improvements in survival rates of
childhood cancers make more apparent the later ef-
fects of life-saving cancer therapies. Stroke is a par-
ticularly devastating consequence that can not only
lead to physical disability, but can worsen the cog-
nitive impairment that many survivors develop as a
direct effect of cranial radiation therapy, or the
cancer itself. A better understanding of risk factors
for stroke, and the underlying mechanisms, creates
opportunities for primary and secondary stroke
prevention. A role for accelerated atherosclerosis
suggests particularly low-hanging fruit for risk
modification in this population: the early identifi-
cation and treatment of modifiable atherosclerotic
risk factors like hypertension. Screening guidelines
might need to be adjusted to assess for these risk
factors in a more uniform way in this at-risk
population.
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